Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant

Paul GlueDunedin School of Medicine, Otago, New ZealandCorrespondence[email protected]

Colleen LooSchool of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia

Anthony RodgersThe George Institute for Global Health, the University of Sydney, Sydney, Australia

Verònica GálvezSchool of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia

Andrew A. SomogyiSchool of Medicine, University of Adelaide, Adelaide, Australia

Philip B. MitchellSchool of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia

References

Cooper MD, Rosenblat JD, Cha DS, Lee Y, Kakar R, Mclntyre RS. 2016. Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. World J Biol Psychiatry. E-pub ahead of print. doi:10.3109/15622975.2016.1139747
Google Scholar
Correll GE, Futter GE. 2006. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 7:92–95.
Google Scholar
Grott Zanicotti C, Perez D, Glue P. 2013. Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 16:719–720.
Google Scholar
Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 76:970–976.
Google Scholar
Lai R, Katalinic N, Glue P, Somogyi A, Mitchell P, Leyden J, Harper S, Loo C. 2014. Pilot dose-response trial of IV ketamine in treatment-resistant depression. World J Biol Psychiatry. 15:579–584.
Google Scholar
Loo CK, Gálvez V, O’Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, et al. 2016. Placebo-controlled pilot trial testing dose-titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica. E-pub ahead of print. doi:10.1111/acps.12572
Google Scholar
Xu Y, Hackett M, Carter G, Loo CK, Gálvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi A, et al. 2016. Effects of low-dose and very low-dose dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharm. 19:pyv124. doi:10.1093/ijnp/pyv124
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date